Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Therapeutic implications of the emerging molecular biology of uveal melanoma.

Patel M, Smyth E, Chapman PB, Wolchok JD, Schwartz GK, Abramson DH, Carvajal RD.

Clin Cancer Res. 2011 Apr 15;17(8):2087-100. doi: 10.1158/1078-0432.CCR-10-3169. Epub 2011 Mar 28.

2.

Ocular melanoma: what's new?

Leyvraz S, Keilholz U.

Curr Opin Oncol. 2012 Mar;24(2):162-9. doi: 10.1097/CCO.0b013e32834ff069. Review.

PMID:
22234256
3.

Metastatic uveal melanoma: biology and emerging treatments.

Woodman SE.

Cancer J. 2012 Mar-Apr;18(2):148-52. doi: 10.1097/PPO.0b013e31824bd256. Review.

4.

Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.

Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE.

Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.

5.

Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.

Ambrosini G, Pratilas CA, Qin LX, Tadi M, Surriga O, Carvajal RD, Schwartz GK.

Clin Cancer Res. 2012 Jul 1;18(13):3552-61. doi: 10.1158/1078-0432.CCR-11-3086. Epub 2012 May 1.

6.

Targeted therapy for uveal melanoma.

Triozzi PL, Eng C, Singh AD.

Cancer Treat Rev. 2008 May;34(3):247-58. doi: 10.1016/j.ctrv.2007.12.002. Epub 2008 Jan 28. Review.

PMID:
18226859
7.

Uveal melanoma and macular degeneration: molecular biology and potential therapeutic applications.

Economou MA.

Acta Ophthalmol. 2008 Dec;86(8):930-1. doi: 10.1111/j.1755-3768.2008.01188.x.

8.

The molecular pathology of cutaneous melanoma.

Bogenrieder T, Herlyn M.

Cancer Biomark. 2010;9(1-6):267-86. doi: 10.3233/CBM-2011-0164. Review.

PMID:
22112480
9.

Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.

Ambrosini G, Musi E, Ho AL, de Stanchina E, Schwartz GK.

Mol Cancer Ther. 2013 May;12(5):768-76. doi: 10.1158/1535-7163.MCT-12-1020. Epub 2013 Feb 26.

10.

The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.

Musi E, Ambrosini G, de Stanchina E, Schwartz GK.

Mol Cancer Ther. 2014 May;13(5):1044-53. doi: 10.1158/1535-7163.MCT-13-0550. Epub 2014 Feb 21. Erratum in: Mol Cancer Ther. 2014 Sep;13(9):2250.

11.

Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD.

Pigment Cell Melanoma Res. 2015 Mar;28(2):135-47. doi: 10.1111/pcmr.12304. Epub 2014 Sep 1. Review.

12.

Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.

Wu X, Li J, Zhu M, Fletcher JA, Hodi FS.

Mol Cancer Ther. 2012 Sep;11(9):1905-14. doi: 10.1158/1535-7163.MCT-12-0121. Epub 2012 May 31.

13.

Uveal melanoma.

Spagnolo F, Caltabiano G, Queirolo P.

Cancer Treat Rev. 2012 Aug;38(5):549-53. doi: 10.1016/j.ctrv.2012.01.002. Epub 2012 Jan 24. Review.

PMID:
22270078
14.

What hope for the future? GNAQ and uveal melanoma.

Sisley K, Doherty R, Cross NA.

Br J Ophthalmol. 2011 May;95(5):620-3. doi: 10.1136/bjo.2010.182097. Epub 2011 Mar 3. Review.

PMID:
21378004
15.

Mutations in GNA11 in uveal melanoma.

Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O'Brien J, Bastian BC.

N Engl J Med. 2010 Dec 2;363(23):2191-9. doi: 10.1056/NEJMoa1000584. Epub 2010 Nov 17.

16.

The biology and management of uveal melanoma.

Sato T, Han F, Yamamoto A.

Curr Oncol Rep. 2008 Sep;10(5):431-8. Review.

PMID:
18706273
17.

Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.

Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, Bastian BC.

Oncogene. 2014 Sep 25;33(39):4724-34. doi: 10.1038/onc.2013.418. Epub 2013 Oct 21.

18.

Recent developments in prognostic and predictive testing in uveal melanoma.

Field MG, Harbour JW.

Curr Opin Ophthalmol. 2014 May;25(3):234-9. doi: 10.1097/ICU.0000000000000051. Review.

19.

Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.

Ye M, Hu D, Tu L, Zhou X, Lu F, Wen B, Wu W, Lin Y, Zhou Z, Qu J.

Invest Ophthalmol Vis Sci. 2008 Feb;49(2):497-504. doi: 10.1167/iovs.07-0975.

PMID:
18234991
20.

Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.

Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino G, Sodhi A, Chen Q, Gutkind JS.

Cancer Cell. 2014 Jun 16;25(6):831-45. doi: 10.1016/j.ccr.2014.04.016. Epub 2014 May 29.

Items per page

Supplemental Content

Write to the Help Desk